Evolocumab lowers LDL-C in patients with familial hypercholesterolaemia
19 Feb 2020
byStephen Padilla
Evolocumab therapy demonstrates long-term efficacy, safety and tolerability in patients with homozygous (HoFH) and severe heterozygous familial hypercholesterolaemia (HeFH), reducing plasma low-density lipoprotein cholesterol (LDL-C) as well as the need for LDL apheresis, a study has shown.